Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
17-AAG (HB3599)
Description:Selective Hsp90 inhibitor. Also protects neuroprogenitor cells against apoptosis.
Purity:>98%
Acetomycin (HB3734)
Description:Antibiotic with antibacterial, antifungal and antiprotozoal activity
Purity:>98%
Ambuic acid (HB3759)
Description:Antibiotic with antibacterial and antifungal activities
Purity:>95%
Anisomycin (HB2239)
Description:Protein synthesis inhibitor. Potent JNK / p38 MAPK activator.
Purity:>98%
Aphidicolin (HB3690)
Description:DNA replication inhibitor. Useful for cell synchronization
Purity:>98%